Key Points
- Director Joshua Levine bought 10,000 EDAP shares at $4.22 each, spending $42,200 and increasing his stake by 40% to 35,000 shares.
- EDAP stock was up 2.0% and opened at $4.16, while the company’s market cap stood at about $155.9 million.
- The company recently reported a quarterly EPS miss of -$0.24 versus -$0.22 expected, even though revenue of $20.48 million came in above estimates; analysts currently rate the stock a Hold with a $6.00 average price target.
Edap Tms S.A. (NASDAQ:EDAP - Get Free Report) Director Joshua Levine bought 10,000 shares of the stock in a transaction on Monday, May 11th. The shares were acquired at an average cost of $4.22 per share, for a total transaction of $42,200.00. Following the completion of the transaction, the director directly owned 35,000 shares of the company's stock, valued at approximately $147,700. The trade was a 40.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Edap Tms Trading Up 2.0%
Edap Tms stock opened at $4.16 on Thursday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The company has a market capitalization of $155.92 million, a price-to-earnings ratio of -5.14 and a beta of -0.10. Edap Tms S.A. has a one year low of $1.21 and a one year high of $5.05. The company's fifty day moving average price is $3.70 and its two-hundred day moving average price is $3.42.
Edap Tms (NASDAQ:EDAP - Get Free Report) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $20.48 million for the quarter, compared to analyst estimates of $19.46 million. Edap Tms had a negative return on equity of 137.61% and a negative net margin of 41.47%. On average, analysts forecast that Edap Tms S.A. will post -0.82 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Edap Tms
A number of hedge funds have recently bought and sold shares of the company. Lido Advisors LLC bought a new stake in shares of Edap Tms in the first quarter valued at about $40,000. SmartHarvest Portfolios LLC bought a new stake in shares of Edap Tms in the first quarter valued at about $38,000. Flax Pond Capital LLC bought a new stake in shares of Edap Tms in the fourth quarter valued at about $2,623,000. Kovack Advisors Inc. bought a new stake in shares of Edap Tms in the fourth quarter valued at about $53,000. Finally, Rock Springs Capital Management LP lifted its stake in shares of Edap Tms by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider's stock valued at $4,233,000 after buying an additional 16,500 shares during the period. 62.74% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several research firms have commented on EDAP. Wall Street Zen downgraded shares of Edap Tms from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. HC Wainwright lowered their target price on shares of Edap Tms from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday, April 9th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Edap Tms has a consensus rating of "Hold" and an average price target of $6.00.
View Our Latest Stock Analysis on Edap Tms
Edap Tms Company Profile
(
Get Free Report)
Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm's core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms's Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.
Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
